open access
Diagnosis of myelodysplastic syndromes in Poland: Polish Adult Leukemia Group (PALG) 2021 recommendations
Affiliations- Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland
- Department of Hematology, Institute of Hematology and Transfusiology, Warsaw, Poland
- Department of Hematology, Jagiellonian University, Collegium Medicum, Kraków, Poland
- Department of Hematology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration’s Hospital, Olsztyn
- Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland
- Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland
- Department of Clinical Genetics, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, Torun
- Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland
- Department of Cancer Prevention and Therapy, Wroclaw Medical University, Wrocław, Poland
- Department of Hematology, Medical University of Lodz, Łódź, Poland
- Department of Hematology, Ludwik Rydygier Hospital, Krakow, Poland
open access
Abstract
Abstract
Keywords
myelodysplastic syndromes, diagnosis, recommendations
About this articleTitle
Diagnosis of myelodysplastic syndromes in Poland: Polish Adult Leukemia Group (PALG) 2021 recommendations
Journal
Issue
Article type
Guidelines / Expert consensus
Pages
3-18
Published online
2021-12-31
Page views
2305
Article views/downloads
395
DOI
10.5603/AHP.a2022.0001
Bibliographic record
Acta Haematol Pol 2022;53(1):3-18.
Keywords
myelodysplastic syndromes
diagnosis
recommendations
Authors
Krzysztof Mądry
Joanna Drozd-Sokołowska
Karol Lis
Bożena Katarzyna Budziszewska
Bartłomiej Pogłódek
Rafał Machowicz
Edyta Subocz
Katarzyna Wiśniewska-Piąty
Tomasz Wróbel
Jan Maciej Zaucha
Ewa Zarzycka
Olga Haus
Ewa Karakulska-Prystupiuk
Lidia Gil
Aleksandra Butrym
Agnieszka Tomaszewska
Grzegorz W. Basak
Anna Waszczuk-Gajda
Agnieszka Pluta
Paweł Szwedyk
Małgorzata Jarmuż-Szymczak
Jagoda Rytel
Jadwiga Dwilewicz-Trojaczek
References (27)- Mądry K, Machowicz R, Waszczuk-Gajda A, et al. Demographic, hematologic, and clinical features of myelodysplastic syndrome patients: results from the First Polish Myelodysplastic Syndrome Registry. Acta Haematol. 2015; 134(2): 125–134.
- Drozd-Sokołowska JE, Mądry K, Waszczuk-Gajda A, et al. Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. Eur J Haematol. 2017; 98(2): 154–159.
- Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109(8): 1536–1542.
- Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016; 91(5): E280–E283.
- Goldberg SL, Chen Er, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28(17): 2847–2852.
- Della Porta MG, Travaglino E, Boveri E, et al. Rete Ematologica Lombarda (REL) Clinical Network. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015; 29(1): 66–75.
- Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017; 8(43): 73483–73500.
- Valent P. ICUS, IDUS, CHIP and CCUS: diagnostic criteria, separation from MDS and clinical implications. Pathobiology. 2019; 86(1): 30–38.
- Hasserjiann R, Orazi A, Brunning R. et al. Myelodyslastic syndromes: overview. In: Swerdlow S, Campo E, Harris N. ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed. Vol. 2. International Agency for Research on Cancer, Lyon 2017: 98–106.
- Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012; 30(8): 820–829.
- Cherry AM, Brockman SR, Paternoster SF, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res. 2003; 27(12): 1085–1090.
- Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009; 94(8): 1066–1074.
- van de Loosdrecht AA, Westers TM. Cutting edge: flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw. 2013; 11(7): 892–902.
- Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014; 28(9): 1793–1798.
- Zheng G, Chen P, Pallavajjalla A, et al. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. Am J Hematol. 2019; 94(10): 1141–1148.
- Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22): 3616–3627.
- Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2): 241–247.
- Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020; 136(2): 157–170.
- Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020; 26(10): 1549–1556.
- University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016; 128(14): 1800–1813.
- Kraft IL, Godley LA, Kraft IL, et al. Identifying potential germline variants from sequencing hematopoietic malignancies. Blood. 2020; 136(22): 2498–2506.
- Peterson L, Bloomfield C, Niemeyer C, Godley L. et al. Myeloid neolasms with germline redisosition. In: Swerdlow S, Camo E, Harris N. et al. ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed. Vol. 2. International Agency for Research on Cancer, Lyon 2017: 121–128.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6): 2079–2088.
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12): 2454–2465.
- Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011; 96(3): 441–449.
- Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30): 7594–7603.
- Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26): 2496–2506.